Austria's LifeTaq collapses after failing to replace animal testing in drug research

LifeTaq, an Austrian biotech startup focused on replacing animal testing in drug research, has filed for insolvency. The company aimed to create a fully automated system for 3D tissue models as a more ethical and scientifically advanced alternative.

Founded with the goal of eliminating animal testing, LifeTaq secured €3.5 million in funding from the Austrian Research Promotion Agency (FFG) and private investors. In autumn 2022, it also launched a crowdfunding campaign, raising over €300,000 from public supporters.

Despite financial backing, the company's situation worsened over time. Credit protection agencies KSV1870 and AKV later concluded that continuing operations was no longer feasible. LifeTaq had projected profitability by 2027, expecting to earn up to €4 million from selling four of its specialised machines.

The startup's technology centred on a fully automated culture machine designed to grow 3D tissue models. This approach was intended to offer a more reliable and ethical method for drug testing compared to traditional animal experiments.

The insolvency filing marks the end of LifeTaq's efforts to revolutionise drug testing. The company's closure follows a period of financial decline, despite earlier funding and public support. Its technology will no longer be developed under the current structure.